Plasma fetuin-A levels and the risk of type 2 diabetes - PubMed (original) (raw)

. 2008 Oct;57(10):2762-7.

doi: 10.2337/db08-0538. Epub 2008 Jul 15.

Affiliations

Plasma fetuin-A levels and the risk of type 2 diabetes

Norbert Stefan et al. Diabetes. 2008 Oct.

Abstract

Objective: The liver-secreted protein fetuin-A induces insulin resistance in animals, and circulating fetuin-A is elevated in insulin resistance and fatty liver in humans. We investigated whether plasma fetuin-A levels predict the incidence of type 2 diabetes in a large prospective, population-based study.

Research design and methods: A case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study comprising 27,548 subjects was designed. We randomly selected a subcohort of 2,500 individuals of whom 2,164 were diabetes free at baseline and had anamnestic, anthropometrical, and metabolic data for analysis. Of the 849 incident diabetic case subjects identified in the full cohort during 7 years of follow-up, 703 remained for analyses after similar exclusions.

Results: Plasma fetuin-A levels were positively associated with diabetes risk after adjustment for age (relative risk [RR] for extreme quintiles 1.75 [95% CI 1.32-2.31]; RR for 10 mug/ml 1.04 [1.03-1.06]). The association remained significant after adjustment for sex, BMI, waist circumference, and lifestyle risk factors (RR for 10 mug/ml 1.03 [1.01-1.06]). Adjustment for glucose, triglycerides, HDL cholesterol, A1C, gamma-glutamyltransferase, or high-sensitivity C-reactive protein or mutual adjustment for these biomarkers did not appreciably change this result (RR for 10 mug/ml full adjusted model 1.05 [1.02-1.07]). Furthermore, fetuin-A was associated with increased diabetes risk particularly in individuals with elevated plasma glucose.

Conclusions: Our data suggest that fetuin-A is an independent risk factor of type 2 diabetes.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

Age-adjusted RR of type 2 diabetes by quintiles of plasma fetuin-A (μg/ml) among men and women in the EPIC-Potsdam Study. P for trend <0.001. Medians (ranges) for quintiles are as follows: quintile 1, 162 μg/ml (14–184); quintile 2, 202 μg/ml (185–214); quintile 3, 227 μg/ml (215–240); quintile 4, 255 μg/ml (241–271); quintile 5, 295 μg/ml (272–442).

FIG. 2.

FIG. 2.

RR of type 2 diabetes per 1 SD of plasma fetuin-A with varying adjustment for metabolic risk markers among men and women in the EPIC-Potsdam Study. RRs were adjusted for age, sex, BMI, waist circumference, education (in or no training, vocational training, technical school, or technical college or university degree), occupational activity (light, moderate, or heavy), sport activity (0, 0.1–4, or >4 h/week), cycling (0, 0.1–2.4, 2.5–4.9, or ≥5 h/week), smoking (never, past, or current <20 cigarettes/day or current ≥20 cigarettes/day), and alcohol intake (0, 0.1–5, 5.1–10, 10.1–20, 20.1–40, or >40 g/day).

FIG. 3.

FIG. 3.

RR of type 2 diabetes per 1 SD of plasma fetuin-A for subgroups of sex, fasting status, abdominal obesity, and glucose levels in the EPIC-Potsdam Study. RRs were adjusted for age, sex BMI, waist circumference, education (in or no training, vocational training, technical school, or technical college or university degree), occupational activity (light, moderate, or heavy), sport activity (0, 0.1–4, or >4 h/week), cycling (0, 0.1–2.4, 2.5–4.9, or ≥5 h/week), smoking (never, past, or current <20 cigarettes/day or current ≥20 cigarettes/day), and alcohol intake (0, 0.1–5, 5.1–10, 10.1–20, 20.1–40, or >40 g/day), HDL cholesterol, triglycerides, glucose, A1C, γ-glutamyltransferase, and hs-CRP (all log transformed). Abdominal obesity was defined as waist ≥102 cm among men or ≥88 cm among women. High glucose was defined as ≥100 mg/dl.

FIG. 4.

FIG. 4.

Schematic overview of the effects of circulating fetuin-A on target tissues. Increase in obesity, particularly in visceral fat mass, results in an increase of liver fat. By yet-unknown mechanisms, this is associated with increased production of fetuin-A (11,23). Elevated circulating fetuin-A directly inhibits insulin signaling in muscle and liver (–9) and results in systemic subclinical and adipose tissue inflammation (19). Under a normal β-cell function, fetuin-A–induced insulin resistance and effects of subclinical inflammation on the β-cells may be compensated; however, the existence of impaired β-cell function results in fetuin-A–induced type 2 diabetes.

Similar articles

Cited by

References

    1. Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, Hayflick L, Butler RN, Allison DB, Ludwig DS: A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 352: 1138–1145, 2005 - PubMed
    1. Stumvoll M, Goldstein BJ, van Haeften TW: Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333–1346, 2005 - PubMed
    1. Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF: Adiponectin and protection against type 2 diabetes mellitus. Lancet 361: 226–228, 2003 - PubMed
    1. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 360: 57–58, 2002 - PubMed
    1. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436: 356–362, 2005 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources